Galapagos, Gilead in $2.2B Deal for T-Cell Engager Autoimmune Therapy
Event summary
- Galapagos and Gilead in advanced talks to collaborate on T-cell engager program for autoimmune diseases following Gilead's $1.675B acquisition of Ouro Medicines.
- Galapagos to co-fund 50% of upfront and milestone payments, absorb Ouro's assets, and share development costs until registrational studies.
- Gilead to retain commercialization rights (excluding Greater China) and pay Galapagos 20-23% royalties on net sales.
- Deal would free up to $500M in Galapagos cash for strategic flexibility, including $150M for potential share repurchases.
- OM336 (gamgertamig), the lead asset, has Fast Track and Orphan Drug Designation for AIHA and ITP, with registrational studies expected in 2027.
The big picture
The potential collaboration underscores the growing interest in T-cell engagers for autoimmune diseases, a space where targeted therapies could reduce reliance on chronic immunosuppression. For Galapagos, the deal represents a strategic pivot toward high-value partnerships after years of standalone development. Gilead's acquisition of Ouro Medicines signals its intent to bolster its autoimmune pipeline, complementing its existing strengths in inflammation and oncology.
What we're watching
- Deal Execution
- Whether Galapagos and Gilead can finalize terms and secure regulatory approvals for the collaboration.
- Clinical Progress
- The pace at which OM336 advances through registrational studies and demonstrates efficacy in autoimmune diseases.
- Financial Flexibility
- How Galapagos deploys the newly freed capital to pursue additional strategic transactions or shareholder returns.
Related topics